743 related articles for article (PubMed ID: 26826402)
21. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
22. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.
Liu W; Shia J; Gönen M; Lowery MA; O'Reilly EM; Klimstra DS
Pancreas; 2014 Nov; 43(8):1264-70. PubMed ID: 25058881
[TBL] [Abstract][Full Text] [Related]
23. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
24. Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome.
Plocharczyk EF; Frankel WL; Hampel H; Peters SB
Am J Dermatopathol; 2013 Apr; 35(2):191-5. PubMed ID: 22722469
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
26. [Immunohistochemical examination of MSH2, PMS2, MLH1, MSH6 compared with the analysis of microsatellite instability in colon adenocarcinoma].
Raskin GA; Ianus GA; Kornilov AV; Orlova RV; Petrov SV; Protasova AÉ; Pozharisskiĭ KM; Imianitov EN
Vopr Onkol; 2014; 60(2):47-50. PubMed ID: 24919261
[TBL] [Abstract][Full Text] [Related]
27. [Microsatellite instability of bilateral breast carcinomas is not linked to down-regulated expression of DNA mismatch repair genes].
Kuligina ESh; Morreau N; Imianitov EN
Vopr Onkol; 2010; 56(2):152-5. PubMed ID: 20552889
[TBL] [Abstract][Full Text] [Related]
28. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
29. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
30. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
31. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
32. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.
Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
[TBL] [Abstract][Full Text] [Related]
33. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
[TBL] [Abstract][Full Text] [Related]
34. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
35. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas.
Mojtahed A; Schrijver I; Ford JM; Longacre TA; Pai RK
Mod Pathol; 2011 Jul; 24(7):1004-14. PubMed ID: 21499234
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer.
South CD; Yearsley M; Martin E; Arnold M; Frankel W; Hampel H
Genet Med; 2009 Nov; 11(11):812-7. PubMed ID: 19752738
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
39. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting.
Overbeek LI; Ligtenberg MJ; Willems RW; Hermens RP; Blokx WA; Dubois SV; van der Linden H; Meijer JW; Mlynek-Kersjes ML; Hoogerbrugge N; Hebeda KM; van Krieken JH
Am J Surg Pathol; 2008 Aug; 32(8):1246-51. PubMed ID: 18677806
[TBL] [Abstract][Full Text] [Related]
40. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act".
Sheridan TB; Fenton H; Lewin MR; Burkart AL; Iacobuzio-Donahue CA; Frankel WL; Montgomery E
Am J Clin Pathol; 2006 Oct; 126(4):564-71. PubMed ID: 16938659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
